Patents Represented by Attorney, Agent or Law Firm Jack L. Tribble
  • Vascular endothelial cell growth factor II
    Patent number: 5726152
    Abstract: Vascular endothelial cell growth factor II is purified from the culture media used to maintain mammalian glioma cells. The protein is a heterodimer, stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.
    Type: Grant
    Filed: August 31, 1994
    Date of Patent: March 10, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Marvin L. Bayne, Gregory L. Conn, Kenneth A. Thomas, Jr.
  • Process for preparing 4-tert-butyloxycarbonyl-(S)-piperazine-2-tert-butylcarboxamide
    Patent number: 5723615
    Abstract: An improved process using chiral hydrogenation is described for the synthesis in high yields of a 4-protected-(S)-piperazine-2-tert-butyl-carboxamide, an intermediate for an HIV protease inhibitor.
    Type: Grant
    Filed: June 18, 1996
    Date of Patent: March 3, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Kai Rossen, Steven A. Weissman, Jess Sager, David Askin, Paul J. Reider, Ralph P. Volante
  • Method of disrupting cultured cells using an impinging jet device
    Patent number: 5721120
    Abstract: A novel method of disrupting cells which do not have a cell wall comprises passing suspended cells through a low pressure impinging jet device. This method disrupts the cells, but does not harm the cell products which are liberated.
    Type: Grant
    Filed: October 2, 1996
    Date of Patent: February 24, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Douglas B. Seifert, Frank S. Leu
  • Method for producing a highly enriched population of osteoclast cells
    Patent number: 5719058
    Abstract: Methods of obtaining enriched populations of osteoclast precursor cells which can be released from tissue culture dishes and used for biochemical studies are described. Osteoblastic cells and bone marrow cells are co-cultured. Next a .alpha..sub.v .beta..sub.3 receptor ligand, such as echistatin is used for cell detachment. The result is an 75-95% pure enriched population of tartrate resistant acid phosphatase (TRAP.sup.+) cells, in high yields (2-3.times.10.sup.6 cells per experiment). These cells are mostly mononucleated and based on their characteristics are considered to be pre-fusion osteoclasts (pOC cells). The precursor osteoclasts can be reseeded onto osteoblasts to obtain an enriched population of mature, multinucleated osteoclast cells.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: February 17, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Sevgi B. Rodan, Gregg Wesolowski, Gideon A. Rodan
  • Stably human transfected rodent fibroblast cell line expressing human GABA-A recepotors, and cloned human GABA-A receptor subunit CDNA sequences
    Patent number: 5719057
    Abstract: The present invention relates to a stably co-transfected eukaryotic cell line capable of expressing a GABA-A receptor, particularly a human GABA-A receptor, which receptor comprises at least one alpha, one beta and one gamma subunit; to the cloning of novel cDNA sequences encoding the .alpha.-2, .alpha.-3, .alpha.-5, .alpha.-6 and .beta.-2 subunits of the human GABA-A receptor; and to the use of the cell line in designing and developing GABA-A receptor subtype-selective medicaments.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: February 17, 1998
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Karen Louise Hadingham, Beatrice le Bourdelles, Paul John Whiting, Peter Baxter Wingrove
  • DNA encoding a soluble VEGF inhibitor
    Patent number: 5712380
    Abstract: The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth factor with high affinity but do not result in signal transduction. These soluble forms of the receptor bind VEGF and inhibit its function.
    Type: Grant
    Filed: April 21, 1994
    Date of Patent: January 27, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Kenneth A. Thomas, Jr.
  • DNA encoding bradykinin B1 receptor
    Patent number: 5712111
    Abstract: DNAs encoding bradykinin B.sub.1 receptors from mammalian cells have been cloned and characterized. The recombinant receptor is capable of forming receptors which bind des-Arg.sup.10 kallidin and other B.sub.1 -specific ligands. The DNA has been expressed in recombinant host cells which produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
    Type: Grant
    Filed: April 15, 1994
    Date of Patent: January 27, 1998
    Assignee: Merck & Co., Inc.
    Inventors: David L. Linemeyer, John W. Hess, Joseph A. Borkowski, Kathleen K. Bierilo, John G. Menke
  • Electrochemical oxidation
    Patent number: 5700364
    Abstract: A process for synthesizing the compounds ##STR1## wherein X is halo, consists of, at a minimum, electrochemical oxidation of the allyl acetonide reactant with halide salt in an aqueous system, the desired compounds being useful as intermediates for the synthesis of inhibitors of renin or HIV protease or other proteases.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: December 23, 1997
    Assignee: Merck & Co., Inc.
    Inventor: Kai Rossen
  • DNA encoding glutamate gated chloride channels
    Patent number: 5693492
    Abstract: DNA encoding glutamate and avermectin-sensitive chloride channels have been cloned and characterized. The protein is capable of forming channels selectively opened with either avermectin or glutamate. The cDNA has been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified. Receptor modulators active in the method disclosed herein are useful as ectoparasiticides, antiparasitic, anthelmenthic, acaracidal and insecticide agents.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: December 2, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Doris F. Cully, Joseph P. Arena, Philip S. Paress, Ken K. Liu
  • Process for functional expression of the para cation channel
    Patent number: 5688917
    Abstract: DNAs encoding voltage-activated cation channels have been cloned and characterized. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells.
    Type: Grant
    Filed: September 30, 1996
    Date of Patent: November 18, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Joseph P. Arena, Guoping Feng, Linda M. Hall, Ken Liu, Leonardus H. T. Van Der Ploeg, Peiyi Wang, Jeffrey W. Warmke
  • DNA polymerase extension assay for influenza virus endonuclease
    Patent number: 5660989
    Abstract: An assay for the influenza virus endonuclease has been developed which involves DNA polymerase-catalyzed extension of the viral endonuclease cleavage product using labeled nucleotides and a DNA template containing a 3' region complementary to the product joined to a 5' region consisting of repeated residues. The DNA polymerase coupled assay does not involve gel electrophoretic separation and is amenable to high volume screening of potential inhibitors. Another key feature of the assay is that it is sensitive enough to detect 200 attomoles of product.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 26, 1997
    Assignee: Merck & Co., Inc.
    Inventors: James L. Cole, Lawrence C. Kuo, David B. Olsen
  • CDNA encoding a novel human protein tyrosine phosphatase
    Patent number: 5658756
    Abstract: A novel human protein tyrosine phosphatase (PTP) has been identified and its cDNA has been isolated. This novel PTP, denoted PTP-OB, has a receptor-like three dimensional structure and is present in osteoblasts. PTP-OB is involved in osteoblast differentiation, and modulators of PTP-OB activity in turn modulate osteoblast differentiation, osteoclast differentiation and osteoclast activity.
    Type: Grant
    Filed: December 1, 1994
    Date of Patent: August 19, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Gideon A. Rodan, Su Jane Rutledge, Azriel Schmidt
  • Stably transfected rodent fibroblast cell lines expressing human GABA-.sub.A -receptors
    Patent number: 5652100
    Abstract: The present invention relates to stably co-transfected eukaryotic cell lines capable of expressing a recombinant GABA.sub.A receptor, particularly a recombinant human GABA.sub.A receptor, which comprises at least one alpha, one beta and one gamma subunit; and to the use of the cell line and/or membrane preparation in selecting compounds and designing medicaments which interact with the respective human recombinant GABA.sub.A receptor.
    Type: Grant
    Filed: November 17, 1994
    Date of Patent: July 29, 1997
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Karen Hadingham, Paul John Whiting
  • Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1- benzoxanzin-2-one
    Patent number: 5633405
    Abstract: An improved synthesis of a highly potent HIV reverse transcription inhibitor is disclosed, involving an acetylide and a trifluoromethyl ketone which produces a chiral product in the presence of a chiral amino alcohol.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: May 27, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Andrew S. Thompson, Edward G. Corley, Edward J.J. Grabowski, Nobuyoshi Yasuda
  • DNA encoding canine immunoglobulin E
    Patent number: 5629415
    Abstract: The present invention relates to DNA molecules encoding a canine IgE and species-specific regions of the canine IgE constant region. The invention comprises the DNA molecules, proteins encoded by the DNA molecules, antibodies to the proteins, cells transformed by the DNA molecules, assays employing the transformed cells, compounds identified by the assays and kits containing the DNA molecules or derivatives thereof.
    Type: Grant
    Filed: November 9, 1994
    Date of Patent: May 13, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Gregory F. Hollis, Mayur D. Patel
  • Pneumococcal polysaccharide conjugate vaccine
    Patent number: 5623057
    Abstract: A novel conjugate vaccine comprising partially hydrolyzed, highly purified, capsular polysaccharide (Ps) from Streptococcus pneumoniae bacteria (pneumococci, Pn) linked to an immunogenic carrier protein, is produced by a new process. The conjugate is useful in the prevention of pneumococcal infections. Vaccines comprising a mixture of from one to ten different pneumococcal polysaccharide-immunogenic protein (Pn-Ps-PRO) conjugates induce broadly protective recipient immune responses against the cognate pathogens from which the polysaccharide components are derived. Young children and infants younger than 2 years old, normally unable to mount a protective immune response to the Pn-Ps alone, exhibit protective immune responses upon vaccination with these Pn-Ps-PRO conjugates.
    Type: Grant
    Filed: May 20, 1994
    Date of Patent: April 22, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Stephen Marburg, Richard L. Tolman, Peter J. Kniskern, William J. Miller, Arpi Hagopian, Charlotte C. Ip, John P. Hennessey, Jr., Dennis J. Kubek, Pamela D. Burke
  • DNA encoding canine immunoglobulin A
    Patent number: 5622842
    Abstract: The present invention relates to DNA molecules encoding a canine IgA and species-specific regions of the canine IgA constant region. The invention comprises the DNA molecules, proteins encoded by the DNA molecules, antibodies to the proteins, cells transformed by the DNA molecules, assays employing the transformed cells, compounds identified by the assays and kits containing the DNA molecules or derivatives thereof.
    Type: Grant
    Filed: November 9, 1994
    Date of Patent: April 22, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Gregory F. Hollis, Mayur D. Patel
  • Process to make HIV protease inhibitor from (2S)-4-picolyl-2-piperazine-t-butylcarboxamide
    Patent number: 5618937
    Abstract: A process for making a clinically efficacious HIV protease inhibitor eliminates one step in its synthesis, by an alternative convergent synthesis using 2(S)-4-picolyl-2-piperazine-t-butylcarboxamide as an intermediate.
    Type: Grant
    Filed: March 15, 1995
    Date of Patent: April 8, 1997
    Assignee: Merck & Co., Inc.
    Inventors: David Askin, Kan K. Eng, Paul Reider, Ralph P. Volante
  • Activation of herpes simplex virus protease by kosmotropes
    Patent number: 5618685
    Abstract: Native Herpes Simplex Virus type 1 (HSV type 1) protease has a rather low activity. It has been found however, that the presence of a kosmotropic anion can increase the activity of the protease over 10-fold. This has many advantages, as now assays for protease activity may be run in very small (micromolar and less) amounts of reagents and substrates, and the assays can be run quickly. Activate HSV-1 protease represents a conformational change from native protease.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: April 8, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Paul L. Darke, Dawn L. Hall, Lawrence C. Kuo
  • Hepatitis B virus surface proteins with reduced host carbohydrate content
    Patent number: 5614384
    Abstract: In order to produce hepatitis B virus (HBV) surface proteins in the form of particles with substantially reduced entrapped carbohydrate content, DNA encoding the HBV surface proteins was expressed in a recombinant yeast host which is deficient in its ability to glycosylate proteins. These HBV surface proteins display the antigenie sites genetically encoded by the S domain of the HBV virion envelope open reading frame and contains substantially reduced levels of entrapped carbohydrate when compared with HBsAg particles produced in "wild-type" yeast cells. These particles are useful as a vaccine for both the active and passive treatment or prevention of disease and/or infection caused by HBV or other agents serologically related to HBV.
    Type: Grant
    Filed: January 4, 1995
    Date of Patent: March 25, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Peter J. Kniskern, Arpi Hagopian